Skip to main content

Find Clinical Trials

Home
Conditions
HER2-positive Breast Cancer

Clinical trial condition

HER2-positive Breast Cancer

Explore clinical trials studying HER2-positive Breast Cancer. Study availability and eligibility vary by location and protocol.

202 public trials 83 recruiting studies

Refine in advanced search Browse all conditions

HER2-positive Breast Cancer trial results

Recruiting

Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

NCT06693037

Conditions: HER2-positive Breast Cancer
Locations: Peking University People's Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients

NCT06479460

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +7 more
Locations: Jiangsu Province Hospital Nanjing, Jiangsu, China

View Trial Details

Recruiting

A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

NCT05635487

Conditions: HER2-positive Breast Cancer
Locations: Shengjing Hospital affiliated to China Medical University Shenyang, Liaoning, China

View Trial Details

Recruiting

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

NCT06313086

Conditions: HER2-positive Breast Cancer
Locations: Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China

View Trial Details

Recruiting

The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

NCT06330012

Conditions: HER2-positive Breast Cancer
Locations: Ji-Yeon Kim Seoul, South Korea

View Trial Details

Recruiting

Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study

NCT05433753

Conditions: HER2-positive Breast Cancer
Locations: National Cancer Center Hospital, Japan Chuo-ku, Tokyo, Japan

View Trial Details

Recruiting

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery

NCT06281210

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +8 more
Locations: Istituto di Candiolo IRCCS Candiolo, Turin, Italy

European Institute of Oncology Milan, Italy

View Trial Details

Recruiting

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

NCT06217185

Conditions: Advanced Breast Cancer, HER2-positive Breast Cancer
Locations: The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China

View Trial Details

Recruiting

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

NCT06035016

Conditions: Breast Diseases, Breast Neoplasms, Early-Stage Breast Cancer, +5 more
Locations: Peking Union Medical College Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

NCT05834764

Conditions: HER2-positive Breast Cancer
Locations: JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University Nanjing, Jiangsu, China

View Trial Details